Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides

This article was originally published in The Pink Sheet Daily

Executive Summary

The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.

You may also be interested in...



NeutroSpec Pulled From The Market

FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.

Raising Corporate Taxes Would Put US Investment At Risk, J&J CFO Warns

Raising US corporate taxes would reduce corporate investment in the US and particularly impact jobs, Johnson & Johnson chief financial officer Joseph Wolk cautioned during the company's first quarter sales and earnings call on 20 April.

J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence

The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.

Topics

UsernamePublicRestriction

Register

PS063929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel